CN101506368B - 通过可逆的磷酸三酯电荷中和保护基转导运输核酸 - Google Patents

通过可逆的磷酸三酯电荷中和保护基转导运输核酸 Download PDF

Info

Publication number
CN101506368B
CN101506368B CN200780030587.9A CN200780030587A CN101506368B CN 101506368 B CN101506368 B CN 101506368B CN 200780030587 A CN200780030587 A CN 200780030587A CN 101506368 B CN101506368 B CN 101506368B
Authority
CN
China
Prior art keywords
substituted
nucleic acid
acid construct
alkyl
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780030587.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101506368A (zh
Inventor
史蒂文·F·道蒂
斯科特·G·彼得森
布莱恩·R·米德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN101506368A publication Critical patent/CN101506368A/zh
Application granted granted Critical
Publication of CN101506368B publication Critical patent/CN101506368B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN200780030587.9A 2006-07-12 2007-07-11 通过可逆的磷酸三酯电荷中和保护基转导运输核酸 Expired - Fee Related CN101506368B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83057206P 2006-07-12 2006-07-12
US60/830,572 2006-07-12
PCT/US2007/015966 WO2008008476A2 (en) 2006-07-12 2007-07-11 Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups

Publications (2)

Publication Number Publication Date
CN101506368A CN101506368A (zh) 2009-08-12
CN101506368B true CN101506368B (zh) 2017-02-08

Family

ID=38923923

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780030587.9A Expired - Fee Related CN101506368B (zh) 2006-07-12 2007-07-11 通过可逆的磷酸三酯电荷中和保护基转导运输核酸

Country Status (7)

Country Link
US (1) US20090093425A1 (https=)
EP (1) EP2046964B1 (https=)
JP (2) JP6125741B2 (https=)
CN (1) CN101506368B (https=)
AU (1) AU2007272906B2 (https=)
CA (1) CA2659103C (https=)
WO (1) WO2008008476A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532017A (ja) 2006-02-10 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア ＰＴＤ／ＣＰＰＳへのｄｓＲＮＡ結合ドメイン融合体によるｓｉＲＮＡの導入可能な送達
US8691971B2 (en) 2008-09-23 2014-04-08 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
US10022454B2 (en) 2008-09-23 2018-07-17 Liposciences, Llc Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis
RU2572826C2 (ru) 2008-12-02 2016-01-20 Чиралджен, Лтд. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
WO2010129853A2 (en) * 2009-05-07 2010-11-11 The Regents Of The University Of California TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS
US20120142763A1 (en) * 2009-06-01 2012-06-07 The Regents Of The University Of California Nucleic acid delivery compositions and methods of use thereof
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
US20130065227A1 (en) * 2010-03-04 2013-03-14 Paula J. Bates Methods of increasing macropinocytosis in cancer cells
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
WO2012138846A2 (en) * 2011-04-05 2012-10-11 The Regents Of The University Of California Method and compositions comprising small rna agonist and antagonists to modulate inflammation
AU2012284265B2 (en) 2011-07-19 2017-08-17 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
JP5435016B2 (ja) 2011-12-01 2014-03-05 株式会社デンソー 半導体装置の製造方法
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
US9950001B2 (en) 2012-08-20 2018-04-24 The Regents Of The University Of California Polynucleotides having bioreversible groups
DK2895608T3 (en) 2012-09-12 2019-01-21 Quark Pharmaceuticals Inc DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT
US9932578B2 (en) 2012-09-12 2018-04-03 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to P53 and methods of use thereof
EP2928877B1 (en) * 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
EP2928876B1 (en) * 2012-12-06 2018-01-17 Merck Sharp & Dohme Corp. Nucleoside kinase bypass compositions and methods
US9920377B2 (en) 2013-03-15 2018-03-20 Sutter West Bay Hospitals FALZ for use as a target for therapies to treat cancer
EP3027223A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
US9889200B2 (en) 2013-07-31 2018-02-13 Qbi Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
CN111437395A (zh) 2013-08-29 2020-07-24 希望之城 细胞穿透缀合物及其使用方法
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
JP2019532027A (ja) 2016-08-17 2019-11-07 ソルスティス バイオロジクス，リミティッド ポリヌクレオチド構築物
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
US11236334B2 (en) 2017-08-22 2022-02-01 National University Corporation Nagoya University Modified polynucleotide
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101421301A (zh) * 2006-02-10 2009-04-29 加利福尼亚大学董事会 通过dsRNA结合域与PTD/CPPS的融合物转导运输siRNA

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
CA2079109A1 (en) * 1990-03-29 1991-09-30 John A. Latham Oligonucleotide-transport agent disulfide conjugates
US5733523A (en) * 1990-12-10 1998-03-31 Akzo Nobel N.V. Targeted delivery of a therapeutic entity using complementary oligonucleotides
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6017700A (en) * 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
JP4320054B2 (ja) * 1996-08-13 2009-08-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ポリヌクレオチド送達のための組成物および方法
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6531590B1 (en) * 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6903077B1 (en) * 1999-01-04 2005-06-07 University Of Vermont And State Agricultural College Methods and products for delivering nucleic acids
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
EP1305333A4 (en) * 2000-07-31 2006-04-12 Active Motif PEPTIDE-MEDIATED DELIVERY OF MOLECULES IN CELLS
US6960648B2 (en) * 2000-10-13 2005-11-01 Universite De Lausanne Intracellular delivery of biological effectors
ES2343318T3 (es) * 2002-11-26 2010-07-28 University Of Massachusetts Administracion de arnsis.
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US20060178297A1 (en) * 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
US7166692B2 (en) * 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
WO2004108883A2 (en) * 2003-06-10 2004-12-16 Toolgen, Inc. Transducible dna-binding proteins
CA2529752A1 (en) * 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
WO2005003315A2 (en) * 2003-07-01 2005-01-13 Allele Biotechnology & Pharmaceuticals, Inc. Compositions and methods for peptide-assisted transfection
EP1687017B1 (en) * 2003-10-24 2013-03-06 Gencia Corporation Methods and compositions for delivering polynucleotides
US7514530B2 (en) * 2004-04-26 2009-04-07 Centre National De La Recherche Scientifique Peptide carrier for delivering siRNA into mammalian cells
US20060035815A1 (en) * 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
CA2565685A1 (en) * 2004-05-04 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20060030003A1 (en) * 2004-05-12 2006-02-09 Simon Michael R Composition and method for introduction of RNA interference sequences into targeted cells and tissues
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
US7084248B2 (en) * 2004-07-14 2006-08-01 Gene Tools, Llc Peptide composition and method for delivering substances into the cytosol of cells
CA2574200A1 (en) * 2004-07-21 2006-01-26 Xiao Huang Hybrid wicking materials for use in high performance heat pipes
WO2006023491A2 (en) * 2004-08-16 2006-03-02 The Cbr Institute For Biomedical Research, Inc. Method of delivering rna interference and uses thereof
WO2006036410A2 (en) * 2004-08-27 2006-04-06 The Regents Of The University Of California Protection from and treatment of prion protein infection
WO2006029078A2 (en) * 2004-09-07 2006-03-16 The Regents Of The University Of California Targeting transducible molecules to specific cell types
JP2009532017A (ja) * 2006-02-10 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア ＰＴＤ／ＣＰＰＳへのｄｓＲＮＡ結合ドメイン融合体によるｓｉＲＮＡの導入可能な送達
US20120142763A1 (en) * 2009-06-01 2012-06-07 The Regents Of The University Of California Nucleic acid delivery compositions and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101421301A (zh) * 2006-02-10 2009-04-29 加利福尼亚大学董事会 通过dsRNA结合域与PTD/CPPS的融合物转导运输siRNA

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIAS et.al.DNA-lipid systems,a physical chemistry study.《Brazilian journal of medical and biological research》.2002,第35卷第509－522页. *
Eguchi Akiko et.al.Efficient siRNA delivery by novel PTD-DRBD fusion proteins.《Cell cycle》.2010,第9卷(第3期),第424－425页. *
PAOELLA et.al.Electrosfatic mechanism for DNA bending by bZIP proteins.《Biochemistry》.1997,第36卷第10033－10038页. *

Also Published As

Publication number Publication date
WO2008008476A3 (en) 2008-07-24
EP2046964A2 (en) 2009-04-15
WO2008008476A2 (en) 2008-01-17
CA2659103A1 (en) 2008-01-17
CA2659103C (en) 2019-05-21
EP2046964A4 (en) 2014-05-14
AU2007272906B2 (en) 2013-01-31
AU2007272906A1 (en) 2008-01-17
CN101506368A (zh) 2009-08-12
JP6125741B2 (ja) 2017-05-17
JP2009543783A (ja) 2009-12-10
US20090093425A1 (en) 2009-04-09
EP2046964B1 (en) 2018-07-04
JP2015062421A (ja) 2015-04-09

Similar Documents

Publication Publication Date Title
CN101506368B (zh) 通过可逆的磷酸三酯电荷中和保护基转导运输核酸
AU2023255025B2 (en) Targeting ligands
JP7530927B2 (ja) ５’－シクロ－ホスホン酸修飾ヌクレオチド
JP7485642B2 (ja) 治療化合物用の標的化リガンド
CN102459302A (zh) 核酸递送组合物及其使用方法
KR20240023631A (ko) 신규 치료 전달 모이어티 및 그의 용도
CN107109405A (zh) 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
JP7808963B2 (ja) ＨＩＦ－２アルファ（ＥＰＡＳ１）の発現を阻害するためのＲＮＡｉ剤、その組成物及び使用方法
JP2026506685A (ja) プログラム細胞死リガンド１遺伝子の発現を抑制するためのｓｉＲＮＡ、そのコンジュゲート及び医薬組成物並びにその用途
KR20240082358A (ko) 치료제의 표적화된 전달을 위한 디아민 스캐폴드를 갖는 다가 리간드 클러스터
JP2025535539A (ja) 修飾された短い干渉核酸（ｓｉＮＡ）分子及びその使用
US10022454B2 (en) Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis
HK1131188A (en) Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
WO2024260452A1 (en) Sirna, conjugate which contain sirna, pharmaceutical composition and uses thereof
HK40128806A (zh) 寡核苷酸组合物及其使用方法
TW202517781A (zh) 寡核苷酸結合物之代謝穩定的碳水化合物靶向配體

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131188

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1131188

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170208

Termination date: 20190711

CF01 Termination of patent right due to non-payment of annual fee